Search
Inavolisib
go.drugbank.com/drugs/DB15275ApprovedInvestigational[A264563] Newer PI3K inhibitors, like inavolisib, seek to mitigate this attenuation. … [A264563] Chemotherapeutic agents targeting the PI3K p110α catalytic subunit have shown antitumor activity and a manageable safety profile - some of which are in clinical use, like [alpelisib] - but preclinical
Dimenhydrinate
go.drugbank.com/drugs/DB00985ApprovedInvestigationaleffects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade. … [A33889] When used in large doses, dimenhydrinate has been shown to cause a "high" characterized by hallucinations, excitement, incoordination, and disorientation.
Mixtures: Neo - Emedyl - DrageesSynonyms: N,N-dimethyl-2-diphenylmethoxyethylamine 8-chlorotheophyllinate, 8-chloro-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione - 2-(diphenylmethoxy)-N,N-dimethylethanamine (1:1)Kappadione
go.drugbank.com/drugs/DB09332ApprovedKappadione is a Vitamin K derivative (chemically, it is menadiol sodium diphosphate), previously approved by FDA prior to 1982 and marketed by Lilly Marketing for this drug has been discontinued and is … not available in North America [L1543].
Baclofen
go.drugbank.com/drugs/DB00181ApprovedInvestigationalAlthough originally designed in 1962 to treat epilepsy, baclofen was not effective in treating this condition but instead was shown to reduce spasticity in selected patients. … [A245338] Baclofen was reintroduced in 1971 as a treatment for spasticity and was later approved by the FDA in 1977.
International brands: Nu-BaclofenProducts: Co Baclofen Tablets 10mg, Co Baclofen Tablets 20mgLactic acid
go.drugbank.com/drugs/DB04398ApprovedInvestigationalVet approvedLactic acid was one of active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020.[L14120] … It is produced by fermentation of a sugar source, such as corn or beets, and then, by neutralizing the resulting lactic acid to create a compound having the formula NaC3H5O3.
Mixtures: Dextrose and Electrolyte No. 75, Dextrose and Electrolyte No. 48Abciximab
go.drugbank.com/drugs/DB00054ApprovedWithdrawnAbciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules … It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Amikacin
go.drugbank.com/drugs/DB00479ApprovedInvestigationalVet approvedof patients with the disease who do not respond to traditional treatment. … [F1949] In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population
Synonyms: 1-N-(L(−)-γ-amino-α-hydroxybutyryl)kanamycin A, O-3-AMINO-3-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->4)-O-(6-AMINO-6-DEOXY-.ALPHA.-D-GLUCOPYRANOSYL-(1->6))-N(SUP 3)-(4-AMINO-L-2-HYDROXYBUTYRYL)-2-DEOXY-L-STREPTAMINETazobactam
go.drugbank.com/drugs/DB01606ApprovedInvestigationalPiperacillin-tazobactam was initially approved by the FDA in 1994, and ceftolozane-tazobactam was approved by the FDA in 2014[FDA label], providing wider antibacterial coverage for gram-negative infections … Tazobactam is an antibiotic of the beta-lactamase inhibitor class that prevents the breakdown of other antibiotics by beta-lactamase enzyme producing organisms.
Plozasiran
go.drugbank.com/drugs/DB18997ApprovedInvestigational[L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603] … Plozasiran (ARO-APOC3) is a small interfering RNA (siRNA) that degrades apolipoprotein C-III (apoC-III) mRNA by RNA interference.
Nadolol
go.drugbank.com/drugs/DB01203ApprovedInvestigational[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and … [A34177] Nadolol was granted FDA approval on 10 December 1979.[L7922]
Categories: Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and Thiazides